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First-line treatment of major depression includes administration of a selective serotonin
reuptake inhibitor (SSRI), yet studies suggest that remission rates following two trials of
an SSRI are <50%. The authors examine the putative biological substrates underlying
“treatment resistant depression (TRD)” with the goal of elucidating novel rationales to
treat TRD. We look at relevant articles from the preclinical and clinical literature combined
with clinical exposure to TRD patients. A major focus was to outline pathophysiological
mechanisms whereby the serotonin system becomes impervious to the desired enhance-
ment of serotonin neurotransmission by SSRIs. A complementary focus was to dissect
neurotransmitter systems, which serve to inhibit the dorsal raphe. We propose, based on
a body of translational studies, TRD may not represent a simple serotonin deficit state but
rather an excess of midbrain peri-raphe serotonin and subsequent deficit at key fronto-
limbic projection sites, with ultimate compromise in serotonin-mediated neuroplasticity.
Glutamate, serotonin, noradrenaline, and histamine are activated by stress and exert an
inhibitory effect on serotonin outflow, in part by “flooding” 5-HT1A autoreceptors by sero-
tonin itself. Certain factors putatively exacerbate this scenario – presence of the short arm
of the serotonin transporter gene, early-life adversity and comorbid bipolar disorder – each
of which has been associated with SSRI-treatment resistance. By utilizing an incremental
approach, we provide a system for treating theTRD patient based on a strategy of rescuing
serotonin neurotransmission from a state of SSRI-induced dorsal raphe stasis. This calls
for “stacked” interventions, with an SSRI base, targeting, if necessary, the glutamatergic,
serotonergic, noradrenergic, and histaminergic systems, thereby successively eliminating
the inhibitory effects each are capable of exerting on serotonin neurons. Future studies are
recommended to test this biologically based approach for treatment of TRD.
Keywords: selective serotonin reuptake inhibitors, treatment-resistant depression, glutamate, somatodendritic
5-HT1A autoreceptors, dorsal raphe, hippocampus, lamotrigine, α2-heteroreceptors
INTRODUCTION
Treatment resistant depression (TRD) (Souery et al., 2006) is
commonly regarded as a failure of depression to respond to two
adequate courses of antidepressants (Burrows et al., 1994; Souery
et al., 1999). Results from the STAR*D study indicate that <30%
of patients with major depressive disorder (MDD) remitted to the
selective serotonin reuptake inhibitor (SSRI), citalopram (Trivedi
et al., 2006). Remitter rates for the first two steps of STAR*D sug-
gest that close to half of patients with MDD suffered from TRD. We
expand on previous reviews of the neurobiology of treatment resis-
tance in depression (Trivedi et al., 2008). Neurobiological-based
guidelines as to how to approach this sizeable group of de facto
TRD patients are discussed. This paper provides a comprehen-
sive review about the serotonin system with limited information
about other hypotheses of TRD. We elaborate on the serotonin
system and discuss the glutamatergic hypothesis only in the con-
text of serotonin function in TRD briefly. We recognize that we are
unable to review other hypotheses of TRD more comprehensively
and refer the reader to other sources such as Trivedi et al. (2008) for
alternative hypotheses of TRD. We also refer the reader to a paper
by Sanacora et al. (2012), which elaborates on the glutamatergic
hypothesis of depression. We recognize that our hypothesis may
only account for a portion of serotonin pathophysiology in TRD,
which may be affected by multiple non-biological factors includ-
ing social variables. For instance, quality of living environment, as
suggested by Branchi (2011), who posits that SSRIs do not elevate
mood directly but act as a catalyst by increasing neural plasticity,
and therefore accentuate the effects of environment on mood.
Firstly, we formulate a neurobiological hypothesis for TRD
based on putative function of the serotonin system. Hypotheses
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rest in part on serotonin-related functions in panic-anxiety
(Coplan et al., 1992, 1995). We had previously examined a para-
doxical hyper-vis-à-vis hypo-function of serotonin neurotrans-
mission in panic disorder, which we now extend to mood dis-
orders. Secondly, we utilize specific patterns of SSRI response to
delineate a subgroup of patients who demonstrate an a priori pro-
clivity toward TRD, using a“pharmacological dissection”approach
(Klein, 2008). The patterns may help identification of TRD
patients and“short-cut”patients to effective treatment approaches,
thus avoiding “serial antidepressant non-response.” Thirdly, we
advance the case that TRD responds pharmacologically more like
“bipolar” vis-à-vis “unipolar” depression (Angst et al., 2010; Li
et al., 2012) although this approach is not without contrary evi-
dence (Healy, 2006; Zimmerman et al., 2008). Finally, we propose a
rationale for TRD that invokes the necessity of “stacking” medica-
tions, akin to treatment-resistant hypertension or diabetes, balanc-
ing the risk of polypharmacy versus continued symptomatology.
NEUROBIOLOGY OF THE SEROTONIN SYSTEM IN TRD
THEORIES FOR MECHANISM OF SSRI EFFICACY AND POTENTIAL
SHORTCOMINGS
The serotonin system and SSRIs are a primary area of focus.
The reader is referred to other sources (Trivedi et al., 2008) for
non-response to other agents. SSRI response has been conceptu-
alized based on seminal studies by Blier and De Montigny (1983);
Blier and de Montigny (1987); Artigas et al. (1996). The model
(Blier et al., 1998) aimed to understand the mechanism of SSRI
action. First, the absence of rapid response to SSRIs was attrib-
uted to shut down of dorsal raphe neuronal firing following acute
reuptake blockade and enhancement of negative feedback via
somatodendritic 5-HT1A receptors located on serotonin neuron
cell bodies (Blier et al., 1998). Second, acute suppression of sero-
tonin neuronal firing was mitigated by the acute accumulation
of synaptic serotonin, via serotonin transporter protein blockade,
thus maintaining 5-HT neurotransmission and continued stim-
ulation of post-synaptic 5-HT1A hippocampal receptors. Third,
delay in antidepressant response was accounted for by a delay
in down-modulation of somatodendritic 5-HT1A autoreceptors
following chronic serotonin agonism. Consideration of neuroplas-
tic effects and intracellular transduction cascades (Duman et al.,
1997, 1999, 2000) (Figure 1) following, for instance, post-synaptic
agonism of hippocampal 5-HT1A receptors (Radley and Jacobs,
2002; Santarelli et al., 2003; Fricker et al., 2005; Huang and Her-
bert, 2005, 2006) has been a later development of this model of
SSRI efficacy. The Blier et al. SSRI model has remained ensconced
while the field shifted to examine post-synaptic effects of sero-
tonin neurotransmission including expression of early precursor
gene products, expression of neurotrophic factors, and neuroge-
nesis in the dentate gyrus of the hippocampus (Duman et al.,
1997). However, salutary neurotrophic effects of SSRIs are ren-
dered moot should serotonin neurotransmission be impeded, thus
fundamentally undermining attempts to harness hippocampal
neuroplasticity.
SEROTONIN DEFICIT HYPOTHESIS – HUMAN DATA
A leading hypothesis for SSRI efficacy is that depression results
from a serotonin deficit state (Mann et al., 1996). However, studies
measuring lumbar cerebrospinal fluid 5-hydroxy-indole-acetic
acid (CSF 5-HIAA) in patients with major depression have failed
to detect consistent reductions in CSF 5-HIAA in comparison to
healthy volunteers (Bowers et al., 1969; Papeschi and McClure,
1971; Mendels and Frazer, 1974). One study using positron
emission tomography examined cerebral blood flow patterns in
response to fenfluramine, which induces release of presynaptic
serotonin (Mann et al., 1996). The conclusions supported blunted
regional cerebral blood flow responsivity in patients with major
depression in comparison to controls (Mann et al., 1996), thus sup-
porting the view of a regional serotonin deficit state in MDD. In
addition, the inflammatory model of depression provides support
for low serotonin neurotransmission inducing depression. Proin-
flammatory cytokines, such as interferon-γ, tumor necrosis factor-
α, interleukin-6, and others, divert tryptophan from serotonin
biosynthesis to quinolinic acid production through the kynurenic
acid pathway, thereby decreasing serotonin production (Muller
and Schwarz, 2007). In the latter scenario, a generalized serotonin
deficiency is implied, but this view is complicated by other factors
(see Serotonin and the Dorsal Raphe: The “Serotonin Flooding”
Concept as Impediment to Serotonin Neurotransmission). The
inflammatory model of depression, moreover, only applies to a
subset of patients, raising the question why it has been so difficult
to demonstrate a serotonin deficit state in “non-inflammatory”
depression.
Our contention is that lumbar CSF represents the aggregate of
excessive peri-raphe 5-HIAA and deficient synaptic serotonin at
projection sites. Data from our laboratory support a “high peri-
raphe 5-HT hypothesis” and thus model a condition for potential
SSRI-treatment resistance (see Serotonin and the Dorsal Raphe:
The “Serotonin Flooding” Concept as Impediment to Serotonin
Neurotransmission). Using cisternal CSF taps in adversely reared
non-human primates, we have noted elevations of cisternal CSF
5-HIAA in comparison to normally reared controls in two sepa-
rate cohorts (Coplan et al., 1998; Mathew et al., 2002) and we have
replicated the finding in a third cohort of differentially reared
non-human primates (Fulton et al., 2014). When CSF is drawn
via the cisternal route, which accesses the cerebellopontine angle,
that CSF is expected to preferentially reflect diffusion from peri-
raphe 5-HIAA. Lumbar CSF reflects, we argue, the aggregate of
high raphe 5-HIAA and low fronto-limbic projection concentra-
tions of 5-HIAA. This asymmetric distribution of serotonin – high
midbrain and low prefrontal cortex 5-HT – is supported by find-
ings in completed suicide victims (Bach et al., 2014). Thus, lumbar
CSF 5-HIAA studies may de facto be a flawed method to document
a serotonin deficit state since the aggregate fails to detect regional
deficits. Rather, we endeavor to conceptualize TRD as an aberrant
regional distribution of serotonin, with an ultimate reduction in
serotonin neurotransmission at critical serotonin projection sites.
SEROTONIN AND THE DORSAL RAPHE: THE “SEROTONIN FLOODING”
CONCEPT AS IMPEDIMENT TO SEROTONIN NEUROTRANSMISSION
A number of preclinical studies have elucidated mechanisms by
which the dorsal raphe serotonergic system is modulated. Medial
prefrontal cortex (mPFC) glutamatergic projections to the dorsal
raphe have been described in detail (Celada et al., 2001; Altieri
et al., 2012). Thus, stimulation of the mPFC causes release of
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FIGURE 1 | Normal functioning serotonergic neuron. The schema depicts a
normally functioning serotonin neuron located in the dorsal raphe. A number
of features are highlighted. Glutamatergic afferents arise from layer V
pyramidal neurons of the medial prefrontal cortex (mPFC), which project,
directly via a single axon directly to the dorsal raphe. Activation of 5-HT2A
receptors in the mPFC activates these cortical neurons whereas activation of
5-HT1A receptors diminish glutamatergic outflow from the mPFC. The absence
of rapid response to SSRIs was attributed to the shutdown of dorsal raphe
neuron firing following acute enhancement of a negative feedback loop via
somatodendritic 5-HT1A receptors located on the cell bodies of serotonin
neurons in the dorsal raphe. Increasing norepinephrine neurotransmission
from locus ceruleus firing through α2-heteroreceptors produces inhibition of
dorsal raphe serotonin neuron firing. Histamine exerts an inhibitory effect on
serotonin neuronal firing through histamine H1 receptors. Serotonin
neurotransmission enhances neuroplastic effects and intracellular
transduction cascades following post-synaptic agonism of 5-HT1A receptors
located in the hippocampus, ultimately resulting in an increase in
neurogenesis. Normative neurotransmission at each synaptic junction is
represented by the depiction of five “neurotransmitter molecules” located
within the synaptic junction and five in the presynapse.
serotonin in the dorsal raphe via activation of glutamatergic-
releasing pyramidal layerV neurons. The ensuing increase of extra-
cellular serotonin in the dorsal raphe region inhibits serotonergic
neuronal firing by acting on 5-HT1A presynaptic autoreceptors
thereby decreasing serotonin release in critical projection areas
such as hippocampus and mPFC. Moreover, subsequent failure of
activation of 5-HT1A somatodendritic heteroreceptors on pyra-
midal cells in the mPFC further enhances glutamatergic outflow,
exacerbating excessive serotonin release or what we have dubbed
“serotonin flooding” in the vicinity of the dorsal raphe (Tao et al.,
1997; Valentino et al., 2003; Altieri et al., 2012). Agonists acti-
vating NMDA and AMPA receptors on pyramidal cells in the
mPFC mimic stress-related increases in glutamatergic neurotrans-
mission. NMDA or AMPA receptor activation in mPFC further
increases serotonin release in the dorsal raphe, with the expected
activation of 5-HT1A autoreceptors that decrease dorsal raphe
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serotonergic neuron firing. Thus, stress activates glutamatergic
neurotransmission via NMDA or AMPA receptors in the mPFC
(Musazzi et al., 2010) conceivably “flooding” the dorsal raphe
with serotonin and attenuating serotonin outflow (Figure 2).
According to the inflammatory hypothesis of depression, pro-
duction of quinolinic acid, an NMDA agonist, is preferentially
increased by proinflammatory cytokines. Thus, inflammation also
activates glutamatergic neurotransmission, conceivably contribut-
ing to excessive 5-HT1A autoreceptor agonism and an ensuing
decrease in serotonin neuron firing (Muller and Schwarz, 2007).
In this regard, we inform the readers that we may have selected
references that are preferentially relevant to our hypothesis. By
FIGURE 2 | Serotonergic neurotransmission under stress and/or
hyperglutamatergic states. Glutamatergic excitatory input activates a
small population of serotonin neurons in the posterior part of the dorsal
raphe, which leads to accumulation of extracellular serotonin, spreading to
the anterior regions of the dorsal raphe thereby suppressing serotonin
outflow through activation of somatodendritic 5-HT1A autoreceptors. Stress
induces glutamatergic neurotransmission directed into the dorsal raphe and
stress therefore “floods” the dorsal raphe with serotonin, thus “choking”
serotonin outflow. Activation of 5-HT2A receptors in the mPFC activates
Layer V cortical neurons enhancing glutamatergic input into the dorsal
raphe. High peri-raphe 5-HT has been putatively demonstrated by high
cisternal CSF taps in adversely reared non-human primates where
elevations of CSF 5-HIA have been noted in adversely reared subjects in
comparison to normally reared controls. Glutamate, serotonin,
noradrenaline, and histamine are activated by stress and exert an inhibitory
effect on serotonin outflow, in part, by “flooding” 5-HT1A autoreceptors by
serotonin itself. Factors, which may exacerbate this scenario, such as
presence of the short arm of the serotonin transporter gene, early life
adversity and comorbid bipolar disorder, are generally associated with
SSRI-treatment resistance. An excess of midbrain peri-raphe serotonin is
associated with a subsequent deficit at important fronto-limbic projection
sites, with a compromise in serotonin-mediated neuroplasticity.
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contrast, studies by Rozeske et al. (2011) reveal that uncontrollable
rather than controllable stress leads to desensitization rather than
downregulation of DRN 5-HT1A receptors. This latter manuscript
suggests that our hypothesis does not fully account for certain
studies in the literature that are discrepant with our hypothesis.
ROLE OF 5-HT1A RECEPTOR IN DEPRESSION AND ANXIETY IN ANIMAL
MODELS
In general, serotonergic neuronal firing is under tonic inhibition
of somatodendritic 5-HT1A autoreceptors, and their selective dele-
tion causes an increase in extracellular serotonin in certain brain
projection areas. New molecular techniques, such as RNA inter-
ference, which silences gene expression, are being used to detect
the role of 5-HT1A receptors in depression and anxiety. Collec-
tively, these studies support the contention that attenuation of
5-HT1A autoreceptor function enhances serotonin neuronal fir-
ing. Small interfering RNA (siRNA) contains about 25–50 bp of
double stranded RNA, homologous to the gene to be silenced,
by blocking transcription. Silencing the 5-HT1A receptor gene
by siRNA decreases 5-HT1A receptor expression. In one study in
mice, intracerebroventricular injection of siRNA targeting 5-HT1A
receptor mRNA, coupled with the SSRI sertraline, showed an acute
antidepressant effect in the forced-swim and tail-suspension tests.
When this conjugate was administered via intranasal route, effects
similar to the intracerebroventricular route were observed, thereby
opening new therapeutic strategies (Bortolozzi et al., 2012).
Outcomes of experiments with 5-HT1A receptor knockout
(KO) mice have observed to be dependent on many factors includ-
ing whether the KO receptor is presynaptic (autoreceptor) or
post-synaptic, and the timing of receptor suppression. It has
been observed that lifelong deletion of 5-HT1A receptors in mice
predisposes to anxious behavior (Richardson-Jones et al., 2011).
However, 5-HT1A receptors play a role in neuronal development,
such that complete KO of 5-HT1A receptors from birth may well be
associated with neurodevelopmental effects, which may influence
behavioral outcomes. Inducible suppression of 5-HT1A receptor
provides a methodology of bypassing neurodevelopmental effects
of lifetime KO (Richardson-Jones et al., 2010, 2011). Rodents with
inducible 5-HT1A autoreceptor suppression (low 5-HT1A group)
did not differ in behavioral response to conflict-based anxiety
or an acute stressor in comparison to the high 5-HT1A group.
However, the former had increased mobility to a chronic stressor
in the forced-swim test (Richardson-Jones et al., 2010). 5-HT1A
post-synaptic receptors have been found to be necessary for antide-
pressant effects; hence, 5-HT1A autoreceptor selective antagonism
coupled with post-synaptic 5-HT1A receptor agonism is thought
to produce antidepressant effects (see Bipolar Versus Unipolar
Depression: Data from Animal Models). Thus, further evidence
is provided that 5-HT1A down-modulation plays a critical role
in antidepressant response and has also been implicated in the
expression of mood and anxiety-like behaviors (Richardson-Jones
et al., 2010, 2011; Celada et al., 2013).
ROLE OF SEROTONIN TRANSPORTER IN DEPRESSION
In humans, depression consequent to early-life stress is influenced
by polymorphisms of specific genes that confer a vulnerability
diathesis (Kaufman et al., 2004, 2006; Kendler et al., 2005; Popova
Nina and Naumenko Vladimir, 2013). The serotonin transporter
protein gene, SLC6A4, encodes the serotonin transporter, a protein
critical to the regulation of brain serotonin function (Lesch et al.,
1995). A serotonin transporter polymorphic site that maps to the
promoter region, commonly known as 5-HTTLPR, consists of a
variable number of tandem repeats. There are two common func-
tionally different alleles at 5-HTTLPR, the short (“s”) allele and
the long (“l”) allele. The “s” allele encodes an attenuated promoter
segment, and, relative to the “l” allele, is associated with reduced
transcription and functional capacity of the serotonin transporter
(Lesch et al., 1995). The “l” allele can be subtyped into “La and
Lg” alleles; the latter is thought to be similar to the “s” allele (Frodl
et al.,2008). Studies have therefore examined the clinical influences
of a triallelic (La-Lg-S) system (Stein et al., 2006). Although two
meta-analyses refuted effects of the 5-HTTLPR on the relationship
between concurrent stress and depression (Munafo et al., 2009;
Risch et al., 2009), these have been criticized (Rutter et al., 2009;
Uher and McGuffin, 2010). In addition, a more recent larger meta-
analysis supported the hypothesis that 5-HTTLPR is involved in
the interaction between stress and depression (Karg et al., 2011).
Superior response to SSRIs in depressed patients with the long
allele versus short allele has been reported (Smits et al., 2008;
Gressier et al., 2009; Huezo-Diaz et al., 2009; Min et al., 2009; Illi
et al., 2011), although some studies fail to show allelic effects (Lewis
et al., 2011). Although description of the functional attributes of
the serotonin polymorphism have been contradictory (Karg et al.,
2011), clinical data would prompt us to suspect that the short allele
is associated with an inability of the serotonin transporter to cope
with excess synaptic 5-HT in the somatodendritic raphe area but
this statement remains speculative. Therefore, compromised SSRI
response in patients with the short allele potentially invokes an
autoreceptor mechanism, in that short allele subjects are likely to
accumulate serotonin in the peri-raphe area. Further implicating
the 5-HT1A autoreceptor and the 5-HTTLPR in SSRI response,
antidepressant effects were boosted by the 5-HT1A antagonist,
pindolol, specifically in MDD patients with the short allele sero-
tonin transporter genotype (see below in this section) (Zanardi
et al., 2001). Similarly, poor SSRI response in patients possess-
ing the short allele of the 5-HTTLPR is observed in generalized
social anxiety disorder (Stein et al., 2006) and in panic disor-
der in female patients (Perna et al., 2005). SSRIs may conceivably
exacerbate a condition of insufficient peri-raphe clearing of sero-
tonin in subjects with the short allele serotonin transporter gene.
The expected compensation of autoreceptor down-modulation
to enhanced peri-raphe 5-HT is overwhelmed by the magnitude
of agonism during “flooding” and putatively exceeds the capacity
of the autoreceptor to sufficiently “down-modulate” (Blier et al.,
1998) (Figure 3), a contention supported by 5-HT1A irreversible
KO rodent studies described below (see Bipolar Versus Unipolar
Depression: Data from Animal Models). We speculate that with
inadequate 5-HT1A-autoreceptor down-modulation, restoration
of dorsal raphe firing following SSRI administration cannot be
assured.
ROLE OF 5-HT1A GENES IN DEPRESSION
With regards to the 5-HT1A receptor gene, transcriptional mod-
ifications have been observed in depression (Celada et al., 2013).
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FIGURE 3 | Effect of addition of an SSRI in aTRD patient. SSRI addition
would induce a flood of serotonin in the region of the dorsal raphe and
would tend to shut down serotonin neuronal firing through agonism of
5-HT1A autoreceptors and would tend to exacerbate rather than improve a
deficit state of serotonin at the distal projection site. Raising the dose of the
SSRI, which is common practice in an upward titration strategy, may in fact,
exacerbate the situation of flooding the extracellular fluid with serotonin
and further preventing the possibility of serotonin neurotransmission
enhancement. The serotonin system may impervious to the physiological
process of an increment of SSRI producing a commensurate enhancement
of serotonin neurotransmission. Rather, an increment in SSRI reduces the
likelihood of serotonergic neurotransmission enhancement as the dosage
increase exacerbates the build-up of serotonin in the peri-raphe area, thus
enhancing shutdown of serotonin firing through 5-HT1A-autoreceptor
agonism. Of note, the magnitude of peri-raphe serotonin build-up
overwhelms the capacity of 5-HT1A autoreceptor to down-regulate.
Factors such as glucocorticoids, brain-derived neurotrophic factor
(BDNF), and proteins such as deformed epidermal autoregulatory
factor-1 (Deaf-1), Freud-1, Hes 5, and Hes 1 have been associated
with transcriptional regulation of the 5-HT1A gene (Celada et al.,
2013). Functional polymorphisms in the promoter region of the
Htr1A gene (which codes for 5-HT1A receptors) are associated
with variable response to antidepressants. In mice studies, lack
of the Deaf-1 protein was found to be associated with increased
presynaptic 5-HT1A receptor function/expression and decreased
5-HT1A receptor post-synaptic function/expression (Celada et al.,
2013). Freud-1 is a transcriptional protein that is thought to play
a role in autoregulation of the serotonin system. It has been
observed that chronic activation of 5-HT1A receptors leads to
increased expression of Freud-1, which causes decrease in 5-HT1A
receptor gene expression (Popova Nina and Naumenko Vladimir,
2013). Presence of the C(-1019)G polymorphism in the 5-HT1A
gene promoter region, which prevents 5-HT1A gene repression,
results in higher 5-HT1A receptor expression, explaining failure
of antidepressant response (Celada et al., 2013). Thus, SSRIs may
conceivably exacerbate a reduction in serotonin neuronal firing in
persons with the C(-1019)G polymorphism of the 5-HT1A gene
because of 5-HT1A autoreceptor overexpression.
PERILS OF SSRI DOSAGE INCREASE TO PRE-EXISTING PERI-RAPHE
SEROTONIN
After SSRI initiation, as mentioned previously, an initial eleva-
tion of extracellular serotonin in the peri-raphe region results
in decreased serotonergic firing via 5-HT1A autoreceptor ago-
nism. This is compensated for by the elevated synaptic serotonin
at post-synaptic sites through transporter blockade at the distal
presynaptic site. For an antidepressant response to occur, suffi-
cient down-modulation of 5-HT1A autoreceptors is required to
allow for recovery of firing of the serotonin neurons (Bose et al.,
2011). Raising the SSRI dose in our model of the TRD patient
would putatively exacerbate flooding of peri-raphe extracellular
fluid with serotonin and prevent enhancement of neurotransmis-
sion, leading to non-response (Figure 3). The serotonin system
becomes, under these circumstances, impervious to SSRI dosage
increase, failing to produce the desired enhancement of serotonin
neurotransmission. By contrast, in such patients, SSRI increments
are speculated to reduce the likelihood enhancing of serotonin
neurotransmission as dosage increases conceivably exacerbate the
build-up of serotonin in the peri-raphe area, thereby producing
additional shutdown of serotonin firing through 5-HT1A autore-
ceptor agonism (Figure 3). In the STAR*D, SSRI non-response
appears not attributable to the type of SSRI administered. Switch-
ing to a second SSRI, only achieved a remission rate of <20%
(Rush et al., 2006), suggesting that factors, which rendered the
patient impervious to the first SSRI, largely persisted for the sec-
ond SSRI trial. The corollary is that non-response to a single SSRI is
predictive of continued resistance to SSRIs (Rush et al., 2006). Sus-
tained non-response to escalating SSRI doses is the first indicator
of “failing ‘a putative’ SSRI challenge test” (Table 1).
Alternatively, 5-HT1A autoreceptor antagonism in conjunc-
tion with serotonin transporter reuptake blockade could theo-
retically produce rapid antidepressant effects and alleviate the
effects of “serotonin flooding.” A systematic review of the lit-
erature involving augmentation of SSRIs by pindolol, a 5-HT1A
antagonist, reveals rapid antidepressant effects which were evi-
dent within 2 weeks of pindolol augmentation in certain stud-
ies. But the area has yielded conflicting results (Whale et al.,
2010). This ambiguity may, in part, be due to the non-selective
full blockade of pre- and post-synaptic 5-HT1A receptors by
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Table 1 | Failure of the “SSRI challenge” test-clinical features.
Antidepressant-induced mania
Jitteriness syndrome
Tachyphylaxis
Non-response
The phenomenon of non-response to escalating SSRI doses is the first indicator
of “failure” of a putative “SSRI challenge test.” Other indicators of a failed SSRI
challenge test are exhibiting mania or hypomania, tachyphylaxis (often accompa-
nied by rapid response), and/or paradoxical response to SSRIs. Such individuals
are predicted to respond poorly to future SSRI trials.
pindolol, post-synaptic 5-HT1A receptor activation being neces-
sary for preserving antidepressant effects. Moreover, it was not
clear during the initial pindolol studies that serotonin trans-
porter gene polymorphisms play a critical role in SSRI response.
The new antidepressant, vilazodone, was developed with a simi-
lar concept in mind and has combined 5-HT1A partial agonistic
activity and serotonin transporter reuptake blockade (Hughes
et al., 2005). The crucial difference between vilazodone ver-
sus pindolol augmentation is that the latter is a full antag-
onist whereas the former is a potent partial agonist (Hughes
et al., 2005; Khan, 2009), as is aripiprazole (Stahl, 2001) thus
permitting activation of post-synaptic 5-HT1A receptors (dis-
cussed further in Section “A Psychopharmacological Approach to
Treatment-Resistant Depression”).
BASIS FOR SEROTONIN REUPTAKE ENHANCEMENT AS
ANTIDEPRESSANT
Tianeptine (Stablon) is used for the treatment of MDD in Europe
but not in the US (Lejeune et al., 1988). Tianeptine’s mechanism
of action ostensibly defies logic as it enhances rather than inhibits
reuptake of serotonin at the serotonin transporter site. Human
studies show rapid relief of depressive symptoms (Novotny and
Faltus, 2003) and good tolerability of tianeptine as compared to
SSRIs (Atmaca et al., 2003; Bonierbale et al., 2003). One possible
mechanism of action of tianeptine is that it blocks stress-induced
glutamate transporter-1 mRNA (GLT-1 mRNA) expression and
stress-induced decreases in hippocampal volume (Reagan et al.,
2004). The hypothesis of GLT-1mRNA inhibition underlying the
mechanism of action of tianeptine could be integrated with our
above stated contention. Glutamatergic activation of pyramidal
cells causes increase of dorsal raphe extracellular serotonin. Hence
inhibiting GLT-1mRNA prevents accumulation of dorsal raphe
extracellular serotonin.
Another explanation that may complement tianeptine’s ther-
apeutic mechanism of action is that it is may be best suited
for depression associated with high peri-raphe serotonin. By
presumably clearing the peri-raphe area of 5-HT, the 5-HT1A-
somatodendritic autoreceptor is vacated,and the dorsal raphe neu-
ron can now resume firing. However, the somatodendritic effect
is putatively offset by enhanced synaptic reuptake of serotonin
at projection sites, conceivably depriving post-synaptic 5-HT1A
receptors of serotonin. A PET study by our group, using the McNeil
[11C McN 5652] compound, which labels serotonin transporter,
shows numerically higher concentrations of serotonin transporter
in the raphe area vis-à-vis hippocampus (Kent et al., 2002), thus
raising the possibility that it is tianeptine’s peri-raphe effects that
are most germane to its serotonergic efficacy. Certainly, in animal
models of chronic restraint stress, tianeptine was effective whereas
SSRIs did not reverse stress-induced behavioral and biological
changes (McEwen et al., 2009).
UNTOWARD EFFECTS OF “SSRI CHALLENGE”
Clinical features evident during medication trials may conceivably
predict future SSRI non-response. Information may be gleaned
from observations made during what we have dubbed the “SSRI
challenge” test (Table 1). Thus, a patient may “fail” the “challenge”
imposed by SSRI administration.
ANTIDEPRESSANT-INDUCED MANIA
The first, most obvious, failed outcome is when an SSRI is pre-
scribed for purported unipolar depression and induces mania,
hypomania, rapid cycling, or mixed states. A prior history of bipo-
lar mood disorder is often elicited upon more thorough inquiry.
This form of bipolarity has previously been termed Bipolar III
(Akiskal and Pinto, 1999) stating“a full hypomanic episode emerg-
ing during antidepressant treatment and persisting beyond the
physiological effect of that treatment” (Chun and Dunner, 2004;
Fiedorowicz et al., 2011). Adolescents who have not manifested the
manic component of a bipolar disorder may be particularly vulner-
able to SSRI antidepressant-induced mania or hypomania (Frye
et al., 2009). Although preliminary studies showed conflicting
results regarding the association between 5-HTTLPR polymor-
phism and antidepressant-induced mania (Mundo et al., 2001;
Rousseva et al., 2003; Serretti et al., 2004; Baumer et al., 2006;
Masoliver et al., 2006; Ferreira Ade et al., 2009), a recent meta-
analysis indicated a higher incidence of antidepressant-induced
mania in patients with the “s” variant of 5-HTTLPR (Daray et al.,
2010). Likelihood of SSRI monotherapy response is deemed low
once failure of the “SSRI challenge” test has been observed in
this category. Further discussion regarding unipolar versus bipolar
depression in the context of TRD is discussed below (see Bipolar
Versus Unipolar Depression).
In TRD, an SSRI may conceivably induce hypomania or mania
by excessively increasing distal serotonin outflow because the
“brake” system, which is comprised of 5-HT1A autoreceptors, is
downmodulated following chronic agonism. This hypothesis is
supported by PET imaging (Drevets et al., 1999), which shows
that a familial form of unipolar disorder exhibit reduced ligand
binding of raphe 5-HT1A receptors. A subgroup with the lowest
5-HT1A binding had a positive family history of bipolar disor-
der, which may represent a subthreshold phenotype of bipolar
disorder (Drevets et al., 1999). Thus, precedent exists in the clini-
cal literature for down-modulation of the 5-HT1A “brake” system
specifically in those individuals where we have contended SSRIs
are likely to be ineffective.
JITTERINESS SYNDROME
In the second instance, the patient develops a “paradoxical”
reaction to the SSRI, which may include “the jitteriness syn-
drome”(Gorman et al., 1987). The paradoxical reaction consists of
marked sensitivity to SSRIs with development of increased anxiety,
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jitteriness, or a feeling of “jumping out one’s skin” and worsen-
ing depression and irritability. The paradoxical reaction may be
responsible for the emergence of suicidal ideation in the context
of SSRI administration (Hammad et al., 2006; Perlis et al., 2007).
The occurrence of a paradoxical reaction to an SSRI may not
bode well for future SSRI-treatments because of SSRI intolerance.
In panic disorder, recommendations were to initiate treatment
at low doses with gradual titration. However, a similar reaction
may occur in patients with MDD even without panic disorder
(Beasley et al., 1991, 1992). It was speculated that the reaction
occurred from “upregulated” 5-HT2 receptors with abatement of
the “jitteriness” syndrome and clinical response coinciding with
the down-modulation of 5-HT2 receptors (Gorman et al., 1987).
Alternatively, the jitteriness syndrome may represent an acute shut-
down of dorsal raphe firing to an extent that compromises distal
synaptic cleft serotonin following serotonin reuptake inhibition.
Perlis et al. (2003) report that the jitteriness syndrome was asso-
ciated with excess rates of the “s” allele in accordance with the
notion that there is a build-up of peri-raphe serotonin when trans-
porter reuptake is sluggish and serotonin neurotransmission is
then impeded. This type of clinical presentation is also deemed to
represent a failure of the SSRI “challenge” test.
TACHYPHYLAXIS AND RAPID RESPONSE
The third scenario for failure of the SSRI challenge test is tachy-
phylaxis, or what has commonly been generically termed “poop
out,” in response to an SSRI (Trivedi et al., 2008). Katz reported
high rates of tachyphylaxis on SSRIs when compared to other anti-
depressants, in patients with dysthymia (Katz, 2011). Similarly, a
study by Akiskal et al. (2006) reports a high incidence of hyper-
thymia and hypomania following antidepressant therapy. The lit-
erature describes the existence of a possible “depressive inhibition”
in bipolar disorder that“overshoots” into a hypomanic state (Him-
melhoch, 1998). Despite an extensive literature search, we have not
identified references for the co-occurrence of hyperthymia and
ensuing tachyphylaxis. Anecdotally, many patients who experi-
ence tachyphylaxis are found to have experienced an initial period
of rapid onset hyperthymia occurring within days following SSRI
initiation. This latter phenomenon is a topic that requires further
research. Rapid and dramatic response to an SSRI does not usu-
ally bode well for durability. Quitkin et al. (1998) indicated that
“placebo” response was often accompanied by an acute, remitting-
relapsing pattern, whereas true drug response was associated with
slow and persistent response. Bupropion has been anecdotally
favored for addition to SSRIs to regain treatment response (Poster-
nak and Zimmerman, 2005). It is our contention that tachyphy-
laxis indicates a fundamental inability of serotonin mechanisms
to maintain treatment response, although the mechanisms for the
collapse of serotonin outflow remain unclear. Usually augmen-
tation strategies, described below in the Section “A Psychophar-
macological Approach to Treatment-Resistant Depression,” are
required.
MINIMAL RESPONSE
The fourth scenario is when the patient experiences very little if
any response to an adequate SSRI trial, indicating that attempt-
ing to boost distal synaptic serotonin has failed as a strategy.
In many instances, the non-response has been observed several
times, as was the case in the STAR*D (Rush et al., 2006). We
have already provided a biological model of serial SSRI-treatment
resistance based on glutamatergic-induced flooding of serotonin
activating the 5-HT1A autoreceptors (Valentino et al., 2003; Amat
et al., 2005; Altieri et al., 2012). Activation of 5-HT2A receptors
in the mPFC activates layer V cortical neurons whereas activa-
tion of 5-HT1A receptors diminish glutamatergic outflow from
the mPFC. Thus, 5-HT2A-receptor antagonism in the mPFC, a
receptor-binding feature common to all atypical antipsychotics,
conceivably enhances serotonin outflow by blocking glutamatergic
input into the dorsal raphe. In addition, 5-HT1A partial ago-
nism, an effect of certain atypical agents, may mediate a distal
inhibition of glutamatergic input into the dorsal raphe, thus
retaining integrity of serotonin activation through other affer-
ent sites, such as the lateral habenula (Aghajanian and Wang,
1977; Stern et al., 1981; Kalen and Wiklund, 1989), noradren-
ergic nuclei, substantia nigra, and the spontaneous firing rate
intrinsic to the dorsal raphe neurons (Celada et al., 2001). In sum-
mary, activation of 5-HT2A receptors in the mPFC is associated
with increased glutamatergic tone in the dorsal raphe; a reduc-
tion of serotonin outflow and therapeutic effects of SSRIs will
be overwhelmed. Taken together, “flooding” of the dorsal raphe
5-HT1A-autoreceptors by serotonin surplus is hypothesized to lead
to certain instances of SSRI-treatment resistance. We therefore
complete the four scenarios depicting failure to the SSRI challenge
test that should alert the clinician that success with SSRI agents
is unlikely.
BIPOLAR VERSUS UNIPOLAR DEPRESSION
As described in these four scenarios, the extent to which treatment-
resistant depression overlap with variants of bipolar spectrum
disorder may be great. Studies reveal that the misdiagnosis of bipo-
lar disorder is in the range of approximately 70% and the majority
of those misdiagnosed receive a diagnosis of MDD (Hirschfeld
et al., 2003). It has been well documented that patients with bipo-
lar disorder respond poorly to antidepressants (Sachs et al., 2007).
To what extent, therefore, are TRD samples contaminated by covert
or overt bipolarity? While a recent report showed a nearly 40% rate
of subthreshold hypomania in a group with MDD (Angst et al.,
2010), another study (Perlis et al., 2011) indicated that undiag-
nosed bipolar spectrum disorder did not substantially contribute
to non-response in STAR*D. A comprehensive meta-analysis (Cor-
rea et al., 2010) addressing the issue of whether unrecognized
bipolar disorder is a significant contributor to apparent treat-
ment resistance was deemed to receive moderate support. Less
than moderate support was evinced for the view that relapses dur-
ing ongoing antidepressant treatment (tachyphylaxis) are likely
to have bipolar spectrum disorder although few of the studies
reviewed were specifically designed to address this question. Also,
moderate support was provided for the view that antidepressants
were not “robustly” effective in the face of a bipolar disorder
diagnosis.
The neurobiology of the switch into mania has been discussed
by other investigators (Salvadore et al., 2010). In the current model,
the critical “switch” into mania or hypomania occurs when glu-
tamatergic “inhibition” of the dorsal raphe is no longer active or
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the mPFC no longer provides glutamatergic excitation from its
layer V pyramidal neurons, although the reason for glutamatergic
quiescence remains unclear. The dorsal raphe is now, we posit, rel-
atively free to “overshoot” as the brake system dependent on the
sensitivity of the 5-HT1A autoreceptors has been compromised
by chronic agonism. An excess of serotonin may inundate dis-
tal synaptic sites, which includes the nucleus accumbens (Millan
et al., 2000) where excessive hedonic responses are likely to be
elaborated. Below, in the animal model section, we examine the
plausibility of the aforementioned scenario in mice with selective
5-HT1A autoreceptor KO.
BIPOLAR VERSUS UNIPOLAR DEPRESSION: DATA FROM ANIMAL
MODELS
Rodent models are argued to be relevant to the occurrence of
mania, hypomania, or bipolar type III, specifically in the context
of TRD (Holmes et al., 2003; Ansorge et al., 2004). The first model
entails the study of adult KO mice lacking the gene for, and there-
fore lifelong cessation of serotonin transporter protein expression
(mentioned previously in Section “The Role of 5-HT1A Receptor
in Depression and Anxiety in Animal Models”) (Holmes et al.,
2003). These KO mice purportedly mimic humans monozygotic
for the short arm of the serotonin transporter gene. Concentra-
tion of peri-raphe serotonin is high in comparison to wild-type
mice and dorsal raphe serotonin neurons are in a perpetual state
of hyperpolarization (Lira et al., 2003). Distal synaptic serotonin
concentrations at projection sites such as the hippocampus are,
as predicted, greatly diminished (Holmes et al., 2003). Moreover,
there is a marked down-modulation of 5-HT1A autoreceptors in
the dorsal raphe in response to the chronic agonist activity of
serotonin, but not of sufficient magnitude to sustain normative
rates of serotonin neuronal firing. Thus, there is an upregulation
of post-synaptic 5-HT1A receptors in the hippocampus reflect-
ing the low concentrations of serotonin at the distal synapse.
Once a serotonin 5-HT1A antagonist, such as WAY 100635, is
applied to dorsal raphe neurons, there is a dramatic increase in
dorsal raphe neuronal firing rates since the antagonist preferen-
tially interrupts the hyperactive negative feedback system, eliciting
a rebound overshoot (Holmes et al., 2003). The serotonin “over-
shoot” is argued to mimic serotonin neurotransmission in manic
or hypomanic states in humans, although what the physiological
parallel to 5-HT1A antagonism is remains unclear. A similar sce-
nario has been observed following exposure of rodents to SSRIs
early in life (Ansorge et al., 2004). Such rodents resemble serotonin
transporter KO mice with high peri-raphe serotonin and down-
modulation of 5-HT1A autoreceptors (Ansorge et al., 2004). The
latter data imply that SSRIs administered developmentally may
primarily function in a similar fashion as an irreversible sero-
tonin transporter KO mouse. By contrast, inducible selective KO
of 5-HT1A autoreceptors in mice causes an increase in extracellu-
lar serotonin in the PFC but not in the hippocampus at baseline
(Richardson-Jones et al., 2011). There was, however, a significant
increase in extracellular serotonin in the hippocampus of autore-
ceptor KO mice when an SSRI was administered, while no increase
of extracellular serotonin was found in the PFC following SSRI
administration.
PSYCHOPHARMACOLOGICAL APPROACH TO
TREATMENT-RESISTANT DEPRESSION (FIGURE 4)
Based on the current proposal, we are therefore guided toward
a rational psychopharmacological approach to TRD, which is
deemed relevant to a majority of patients encountered in the
STAR*D study. Drugs with a diverse repertoire of mechanisms
of action may be rationally combined to enhance sluggish sero-
tonin neurotransmission (Millan, 2013). Certainly, polypharmacy
with antipsychotics has been debated for treatment of schizophre-
nia and no clear guidelines exists (Stahl, 2002). A fundamental
basis for the polypharmacy regimen proposed below is admin-
istration of an SSRI as the “augmentation substrate,” despite the
likelihood that patients with TRD will not remit or respond to
an SSRI. Certainly, there are exceptions. For instance, lamotrigine
has been shown effective as monotherapy for the prophylaxis of
mood episodes in Bipolar I patients, both for manic and depressive
recurrence. There is evidence that lamotrigine was more effective
for the prophylaxis of depressive episodes while lithium was more
effective for prophylaxis of manic episodes (Calabrese et al., 2003;
Goodwin et al., 2004). Moreover, quetiapine and lurasidone have
been FDA approved as monotherapy for bipolar depression (Cal-
abrese et al., 2005; Thase et al., 2006; Yatham et al., 2013) and
quetiapine monotherapy was as effective as duloxetine for MDD
(Cutler et al., 2009; McIntyre et al., 2009). However, the combi-
nation of olanzapine and fluoxetine was more effective for TRD
than either drug alone, supporting the utility of an SSRI as an
augmentation substrate (Corya et al., 2006).
The first augmentation agent that we recommend is lamotrig-
ine. One disadvantage is the time required to raise the lamotrigine
dosage. Although a number of lamotrigine augmentation studies
in unipolar depression showed significant antidepressant effect
(Rocha and Hara, 2003; Gutierrez et al., 2005; Gabriel, 2006),
especially in severely treatment-resistant patients (Barbee and
Jamhour, 2002), one study reported negative results (Santos et al.,
2008). Moreover, a recent placebo-controlled study failed to show
significant difference between lamotrigine and placebo as aug-
mentation to paroxetine in unipolar depression (Barbee et al.,
2011). However, two findings reported by this study are consistent
with our recommendation of lamotrigine as the first augmentation
agent in a well-characterized TRD group. First, the study showed
that the antidepressant effect of lamotrigine is more prominent
in treatment-resistant patients, in line with our targeted group.
Second, the data suggested a placebo and lamotrigine separation
by the last visit with completers of 10 weeks treatment approach-
ing significance, an observation that was attributed to the required
slow titration of lamotrigine (Barbee et al., 2011). Taken together,
these data suggest a significant antidepressant effect for lamotrig-
ine augmentation but only when used for a longer period of time
and in TRD patients.
Patients with bipolar “spectrum” disorder, “soft” bipolar disor-
der, or “pseudounipolar” depression (Ghaemi et al., 2000) appear
to respond particularly well to lamotrigine with an SSRI, although
formal studies are lacking. Referring back to our model, a critical
agenda to restoring serotonin outflow is to reduce glutamater-
gic input into the raphe arising from pyramidal cells in layer V
of the mPFC. By acting on sodium and calcium ion channels,
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FIGURE 4 | Points of intervention inTRD. A treatment approach on a
plausible neurobiological model is proposed, which aims to prevent
mPFC-induced serotonin shutting down the dorsal raphe. Utilizing an
incremental approach, lamotrigine is recommended as a first step to curb
glutamatergic inflow to the dorsal raphe. Aripiprazole will further reduce
raphe glutamatergic input by blocking 5-HT2A receptors in the medial
prefrontal cortex and protecting 5-HT1A autoreceptors from serotonin
auto-inhibition through partial 5-HT1A agonism. Quetiapine’s metabolite,
N -desalkyl quetiapine, acts as an antagonist at α2-heteroreceptors, thus
protecting the raphe neurons from shutdown by norepinephrine overdrive.
Finally, drugs like quetiapine also possess potent antihistaminergic effects
for histamine H1 receptors. Histamine through H1 may reduce serotonin
firing. Based on the view that each neurotransmitter system
mentioned – glutamate, serotonin, noradrenaline, and histamine – are
activated by stress and exert a partial inhibitory effect on serotonin
outflow, monotherapy may well be inadequate. Rather, a “stacking”
approach to pharmacotherapy is proposed and creating a formal database
using this method is worthy of pursuing.
lamotrigine inhibits presynaptic release of glutamate (Lees and
Leach, 1993), and thus prevents excessive stimulation of sero-
tonin, which secondarily would impede the shutdown of dorsal
raphe serotonin neuron firing. Two other glutamate modulat-
ing agents have been successfully used in TRD as monotherapy:
(1) riluzole, an FDA approved for amyotrophic lateral sclerosis,
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with a complex mechanism of action including glutamate release
inhibition and reuptake enhancement (Zarate et al., 2004, 2005;
Sanacora et al., 2007), and (2) sub-anesthetic doses of ketamine
infusion, a dissociative anesthetic agent that possesses NMDA
antagonist effects (Berman et al., 2000; Zarate et al., 2006; Valen-
tine et al., 2011). Relevance of the antiglutamatergic effects of
lamotrigine is suggested by the rapid onset of ketamine, also
an antiglutamatergic through inhibition of NMDA receptors. In
the latter case, blockade of excessive glutamatergic input to the
DRN is postulated to occur rapidly. It remains unstudied to what
extent, if at all, serotonin neurotransmission plays a role in the
synaptogenesis and immunomodulation that underlies ketamine’s
antidepressant properties, as reported by Zunszain et al. (2013).
In the case of ketamine, it has been postulated that there is an
increase of AMPA/NMDA neurotransmission, which is thought
to cause an increase in dendritic spine formation in the prefrontal
cortex (Zunszain et al., 2013). Activation by ketamine of the ser-
ine/threonine kinase enzyme, the mammalian target of rapamycin
(mTOR), is reported to cause the observed increase in synapto-
genesis in the prefrontal cortex (Dwyer et al., 2012). The rapid
mTOR mechanism specifically in layer 5 of mPFC entails dendritic
spine increases and may well affect the pyramidal neurons that
constitute afferents to the DRN (Li et al., 2010). It could also, how-
ever, be posited that ketamine effects are mediated downstream
to serotonin modulation. Therefore, ketamine’s mechanism of
action is less affected by the putative upstream serotonin shut-
down. Another caveat is that ketamine’s pharmacological effect
is short but the antidepressant effect lasts for days, presumably
in the absence of NMDA antagonism. Also, sub-anesthetic doses,
of ketamine increase (not decrease) mPFC glutamatergic output.
Therefore it is conceivable, yet unstudied, that the local dorsal
raphe increases in serotonin are NMDA dependent and could
be blocked by ketamine. In summary, the extent to which sero-
tonin neurotransmission plays a role in ketamine’s stimulation of
synaptogenesis and immunomodulation remains unstudied.
The next step we recommend is addition of aripiprazole to the
pre-existing regimen. We refer to the addition of successive aug-
menting strategies as “stacking,” rather than using one augmenta-
tion agent at a time. Stacking or polypharmacy has been essential
for medical conditions such as diabetes and treatment-resistant
hypertension to achieve clinical response by targeting disparate
systems with similar physiological effects (Munger, 2010). The
combination of drugs with divergent mechanisms of action and
targeting of serotonin neurotransmission through diverse mech-
anisms may similarly achieve better outcomes in TRD, with the
potential for reduced cumulative dosing of each medication used
and minimizing side effect profiles (Munger, 2010). There may be
multiple points at which the serotonin system may be compro-
mised in TRD and in some individuals, it may be incumbent to
address each of these inhibitory inputs until serotonin outflow is
fully restored and clinical response, if not remission, is attained.
Adding aripiprazole further attempts to impede exuberant nega-
tive feedback at the 5-HT1A autoreceptors by possessing a potent
5-HT1A partial agonist (Jordan et al., 2002). Since the peri-raphe
concentration of serotonin is posited to be high, aripiprazole is
predicted to act more as a full 5-HT1A antagonist rather than a
partial 5-HT1A agonist, producing a rebound surge in serotonin
outflow (Artigas et al., 2006) putatively aided by the reduction of
glutamatergic outflow by lamotrigine. The FDA approval of arip-
iprazole as an augmenting agent for partially responsive depression
separated from placebo by 1 week (Berman et al., 2009) suggest-
ing that the mechanism of action was not delayed by the necessity
for 5-HT1A autoreceptor down-modulation. No formal studies we
are aware of have been conducted combining an SSRI, lamotrigine,
and aripiprazole. There is, however, a neurobiological rationale for
the “stacking” of these two medications with an SSRI by virtue
of utilizing two distinct mechanisms for preventing serotonin
neurotransmission from shutdown following excessive negative
feedback.
A question arises regarding the comparability of utility of arip-
iprazole, an atypical antipsychotic with 5-HT1A partial agonist
properties, combined with an SSRI versus the novel antidepres-
sant, vilazodone (Viibryd), whose mechanism is described above
in Section “Perils of SSRI Dosage Increase to Pre-Existing Peri-
Raphe Serotonin” (Hughes et al., 2005; Khan, 2009). We would
predict that by preventing early phase (<2 weeks) SSRI-mediated
inhibition of dorsal raphe neuronal firing, vilazodone would be
accompanied by a rapid antidepressant response. One study did
indeed show a separation of drug from placebo by 1 week (Khan
et al., 2011). The second pivotal trial failed to replicate the rapid
onset of efficacy (Reed et al., 2012). Additional studies are there-
fore required. Comparative trials between vilazodone and other
SSRIs or the use of vilazodone in TRD patients have not, to our
knowledge, been performed. However, there is a possibility that
aripiprazole also contributes to diminished glutamatergic outflow
at the dorsal raphe by antagonizing 5-HT2A receptors on layer V
pyramidal neurons (Celada et al., 2001), thus additionally con-
tributing to the restoration of serotonin neurotransmission. Thus,
the addition of atypical antipsychotics in general, such as olanzap-
ine, promotes 5-HT2A receptors antagonism, which may represent
an effective proximal mechanism for attenuating glutamatergic
outflow to the dorsal raphe.
When the patient has yet to respond adequately, targeting
the histamine system is proposed. Histamine, a monoamine, is
increased by acute stress (Ito, 2000) and also increases the rodent
stress response (Cote and Yasumura, 1975). Histamine exerts an
inhibitory effect on serotonin neuronal firing through histamine
H1 receptors (Brown et al., 2002). Quetiapine, and in particular
its primary metabolite, N -desalkyl quetiapine (NQuet), are very
potent inhibitors of the H1 receptor (Nikisch et al., 2010), and
may thus facilitate an increase in serotonin neurotransmission via
histaminergic antagonism per se (McIntyre et al., 2007). Rodent
studies of quetiapine and NQuet, a potent norepinephrine reup-
take inhibitor, indicate that the combination of quetiapine with or
without an SSRI potently increases 5-HT neuronal firing through
two mechanisms; via antagonism of α2-heteroreceptors located on
serotonin neurons by NQuet and possibly via direct 5-HT1A ago-
nism by NQuet (Chernoloz et al., 2012). Since many patients with
bipolar depression and/or TRD have previously failed trials with
serotonin–norepinephrine reuptake inhibitors, there may be an
important role for α2 heteroreceptor antagonism in quetiapine’s
action. However, the potent antihistaminergic effects of NQuet
may also contribute to an increase in serotonin neurotransmission
(Dell’Osso et al., 2011).
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Inhibitory influences on dorsal raphe firing may represent indi-
vidual effects of activation of multiple neurotransmitters. In order
to attain full remission, and remove a maximum of inhibitory
effects,“stacking” of pharmacological agents may be necessary. If a
particular agent is found to be inadequately effective but is discon-
tinued before adding the next agent, the next agent has to “make
up the ground” of the now unattended receptor/neurotransmitter
system. “Stacking” is an approach used for treatment of hyperten-
sion (Munger, 2010) but is not advocated for in TRD, a disorder
that may be argued is just as severe, incapacitating and difficult to
treat as hypertension.
There are evidence-using meta-analyses that SNRI’s may pos-
sess superior efficacy to SSRIs when remission is used as the
outcome variable (Thase et al., 2001). By blocking norepinephrine
reuptake, norepinephrine outflow is diminished through agonism
of α2 autoreceptors, which, in turn, diminishes inhibition of dor-
sal raphe serotonin neuron firing by decreasing norepinephrine
neurotransmission through α2-heteroreceptors. Tricyclic antide-
pressants are also potent norepinephrine reuptake inhibitors and
may also be expected to increase serotonin outflow (Charney et al.,
1981), although the class is also credited with sensitizing post-
synaptic 5-HT1A receptors (Blier et al., 1987). Certainly, in our
model of serotonin shutdown there is a cogent argument for reduc-
ing the inhibitory effects of norepinephrine on serotonin neuron
firing.
CONCLUSION
Animal models conceivably elucidate why SSRI-treatment for
depression may underperform in patients with MDD. To sum-
marize, an excess of serotonin is present at 5-HT1A autoreceptors
and a deficit exists at the post-synaptic sites, where the neurotrans-
mitter is required for neurotrophic effects. Certain circumstances
worsen the scenario, including early-life adversity, possession of
the short arm of the serotonin transporter gene polymorphism and
presence of bipolar disorder or bipolar spectrum disorder. We pro-
visionally predict who will perform poorly on SSRIs, as they will
have failed the SSRI challenge test by either exhibiting: mania or
hypomania, tachyphylaxis, paradoxical response, or non-response.
The treatment approach is based on a plausible neurobiological
model, which aims to prevent excess serotonin shutting down the
dorsal raphe. A “stacking” approach to pharmacotherapy is pro-
posed although creating a formal database is a formidable task,
yet one worthy of pursuit. Finally, we provide the caveat that the
current manuscript is speculative in parts, based on clinical obser-
vation but supported by translational neuroscience. We posit that
the manuscript may act as a catalyst for formal testing of proposed
hypotheses and inform treatment of the TRD patient.
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